Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases

Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases IntroductionPrurigo is a common primary chronic skin disease which highly affects quality of life. Clinical subtypes include prurigo nodularis and excoriated (simplex) prurigo, often associated in the same patients. A minor eczematous component may sometimes be associated, but prurigo differs from pruritus associated with other dermatoses such as bullous pemphigoid, atopic dermatitis, Sézary syndrome and scabies. Therapeutic recommendations of prurigo are scarce due to the lack of previously published strong data. Topical corticosteroids, H1‐antihistamine drugs, moisturizing ointments and phototherapy may be non‐effective. Thalidomide has shown clinical benefit, but its long‐term use is limited by side‐effects. Consequently, treatment may be challenging in patients with difficult‐to‐treat prurigo, that is, with failure of conventional therapies.Methotrexate (MTX) is a folic acid antagonist that has proven its efficacy and good tolerance profile in inflammatory dermatoses (atopic dermatitis, psoriasis, bullous pemphigoid). Only one study investigating the efficacy of MTX in 13 patients with prurigo, showing encouraging results, has been published. The aim of our study was to assess the efficacy and safety of MTX in the treatment of difficult‐to‐treat prurigo in a larger series of patients.Materials and methodsIn this retrospective, multicentre study, cases were recruited within six French university dermatology departments, using the coding of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Loading next page...
 
/lp/wiley/treatment-of-prurigo-with-methotrexate-a-multicentre-retrospective-gCv1zE0LAX
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14646
Publisher site
See Article on Publisher Site

Abstract

IntroductionPrurigo is a common primary chronic skin disease which highly affects quality of life. Clinical subtypes include prurigo nodularis and excoriated (simplex) prurigo, often associated in the same patients. A minor eczematous component may sometimes be associated, but prurigo differs from pruritus associated with other dermatoses such as bullous pemphigoid, atopic dermatitis, Sézary syndrome and scabies. Therapeutic recommendations of prurigo are scarce due to the lack of previously published strong data. Topical corticosteroids, H1‐antihistamine drugs, moisturizing ointments and phototherapy may be non‐effective. Thalidomide has shown clinical benefit, but its long‐term use is limited by side‐effects. Consequently, treatment may be challenging in patients with difficult‐to‐treat prurigo, that is, with failure of conventional therapies.Methotrexate (MTX) is a folic acid antagonist that has proven its efficacy and good tolerance profile in inflammatory dermatoses (atopic dermatitis, psoriasis, bullous pemphigoid). Only one study investigating the efficacy of MTX in 13 patients with prurigo, showing encouraging results, has been published. The aim of our study was to assess the efficacy and safety of MTX in the treatment of difficult‐to‐treat prurigo in a larger series of patients.Materials and methodsIn this retrospective, multicentre study, cases were recruited within six French university dermatology departments, using the coding of

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial